HBx公司
清脆的
cccDNA
Cas9
生物
基因敲除
乙型肝炎表面抗原
上皮-间质转换
癌症研究
基因
间充质干细胞
乙型肝炎病毒
转染
分子生物学
下调和上调
病毒学
细胞生物学
病毒
遗传学
作者
Preety Rawal,Dinesh Mani Tripathi,Hamed Hemati,Jitendra Kumar,Purnima Tyagi,Shiv Kumar Sarin,Vikrant Nain,Savneet Kaur
摘要
Abstract Background and Aims Hepatitis B virus X protein (HBx) play a key role in pathogenesis of HBV‐induced hepatocellular carcinoma (HCC) by promoting epithelial to mesenchymal transition (EMT). In this study, we hypothesized that inhibition of HBx is an effective strategy to combat HCC. Methodology and Results We designed and synthesized novel HBx gene specific single guide RNA (sgRNA) with CRISPR/Cas9 system and studied its in vitro effects on tumour properties of HepG2‐2.15. Full length HBx gene was excised using HBx‐CRISPR that resulted in significant knockdown of HBx expression in hepatoma cells. HBx‐CRISPR also decreased levels of HBsAg and HBV cccDNA expression. A decreased expression of mesenchymal markers, proliferation and tumorigenic properties was observed in HBx‐CRISPR treated cells as compared to controls in both two‐ and three‐ dimensional (2D and 3D) tumour models. Transcriptomics data showed that out of 1159 differentially expressed genes in HBx‐CRISPR transfected cells as compared to controls, 70 genes were upregulated while 1089 genes associated with cell proliferation and EMT pathways were downregulated. Conclusion Thus, targeting of HBx by CRISPR/Cas9 gene editing system reduces covalently closed circular DNA (cccDNA) levels, HBsAg production and mesenchymal characteristics of HBV‐HCC cells. We envision inhibition of HBx by CRISPR as a novel therapeutic approach for HBV‐induced HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI